Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The latest guidelines recommend Gemcitabine plus Capecitabine as the first choice of adjuvant
chemotherapy for pancreatic cancer patients in good physical condition. In order to prolong
the survival of patients and improve the cure rate, metronomic chemotherapy with capecitabine
is a safe, effective and economical treatment mode after adjuvant chemotherapy. This study is
trying to determine that compared with observation group, if capecitabine metronomic
medication is a better choice after adjuvant chemotherapy.